AVRO
(NASDAQ)
14.03
+0.0300   (+0.21%)
After Hours: 14.14 +0.1100 (+0.78%)
Volume (24h) Market Cap. Day Range 52w Range
326.63K 581.56M 13.81 - 14.23 9.76 - 29.32
Nov-24-20 04:19AM AVROBIO Announces Closing of Underwritten Public OfferingBusiness Wire
Nov-19-20 10:06AM AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common StockBusiness Wire
04:09AM AVROBIO Announces Proposed Public Offering of Common StockBusiness Wire
Nov-17-20 07:00AM AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy PipelineBusiness Wire
Nov-06-20 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Nov-05-20 07:00AM AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire
06:18AM Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn SituationSimply Wall St.
Oct-29-20 07:00AM AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry DiseaseBusiness Wire
Oct-26-20 07:00AM AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D DayBusiness Wire
Oct-21-20 07:00AM AVROBIO Appoints Dr. Gail Farfel to its Board of DirectorsBusiness Wire
Oct-06-20 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Oct-05-20 07:00AM AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter SyndromeBusiness Wire
Sep-29-20 10:48AM AVROBIO's Gaucher Disease Candidate Gets Orphan Drug StatusZacks
Sep-28-20 07:00AM AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher DiseaseBusiness Wire
Sep-25-20 07:00AM AVROBIO to Present at Two Upcoming Investor ConferencesBusiness Wire
Sep-04-20 07:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Sep-03-20 07:00AM AVROBIO to Present at Three Upcoming Investor ConferencesBusiness Wire
Aug-12-20 09:41AM Did Hedge Funds Make The Right Call On AVROBIO, Inc. (AVRO) ?Insider Monkey
Aug-07-20 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Aug-06-20 07:00AM AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire
Aug-05-20 07:00AM AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceBusiness Wire
Jul-27-20 08:23AM AVROBIO Sees Hammer Chart Pattern: Time to Buy?Zacks
Jul-08-20 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Jul-06-20 07:00AM AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical TrialsBusiness Wire
Jun-29-20 07:00AM AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology OfficerBusiness Wire
Jun-24-20 04:16AM Here is What Hedge Funds Think About AVROBIO, Inc. (AVRO)Insider Monkey
May-14-20 07:00AM AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020Business Wire
May-13-20 07:00AM AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and CystinosisBusiness Wire
May-09-20 08:36AM We're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn RateSimply Wall St.
May-08-20 08:42AM Why Earnings Season Could Be Great for AVROBIO (AVRO)Zacks
May-07-20 07:00AM AVROBIO Reports 1Q 2020 Financial Results and Provides Business UpdateBusiness Wire
May-06-20 07:00AM AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene TherapiesBusiness Wire
May-05-20 07:00AM AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020Business Wire
May-04-20 07:00AM AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform GloballyBusiness Wire
Apr-14-20 08:58AM Is AVROBIO (AVRO) Stock a Solid Choice Right Now?Zacks
Apr-12-20 02:26AM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVROPR Newswire
Mar-30-20 04:30AM AVROBIO Outlines Response to COVID-19 and Current Assessment of Business ImpactBusiness Wire
Mar-26-20 07:00AM AVROBIO to Participate in Upcoming April Investor ConferencesBusiness Wire
Mar-25-20 07:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Mar-19-20 12:00PM AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?Zacks
Mar-17-20 05:58AM INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire
01:57AM AVRO LOSS NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Announces Investigation of Securities Claims Against AVROBIO, Inc. – AVROBusiness Wire
Mar-17-20 12:25PM AVRO Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AVROBIO, Inc. and Encourages Investors to Contact the FirmACCESSWIRE
Mar-16-20 07:00AM AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business UpdateBusiness Wire
Mar-09-20 07:00AM AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for CystinosisBusiness Wire
Feb-24-20 07:00AM AVROBIO to Present at the Cowen and Company 40th Annual Health Care ConferenceBusiness Wire
Feb-18-20 04:01AM AVROBIO Announces Closing of Underwritten Public OfferingBusiness Wire
Feb-12-20 10:08AM AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common StockBusiness Wire
04:01AM AVROBIO Announces Proposed Public Offering of Common StockBusiness Wire
Feb-11-20 07:23AM The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra OncologyBenzinga
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease. The company is also developing AVR-RD-02 for the treatment of type 1 gaucher disease; AVR-RD-03 for the treatment of pompe disease; and AVR-RD-04 for the treatment of cystinosis. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):